The psychological sciences offer a large spectrum of theories, principles, and methodological approaches to understand mental health, normal and abnormal functions and behaviours, as well as mental disorders. Based on continued research progress, psychology has derived a wide range of effective interventions for behaviour change and the prevention, treatment and rehabilitation of mental disorders. Thus, psychology and clinical psychology in particular should be regarded as the ‘mother' science for psychotherapy and psychotherapeutic practice. This paper provides a selective overview of the scope, strengths and gaps in psychological research to depict the advances needed to inform future research agendas on mental disorders and psychological interventions in the context of psychotherapy. Most maladaptive health behaviours and mental disorders can be conceptualised as the result of developmental dysfunctions of psychological functions and processes, and as associated neurobiological and genetic processes in interaction with behaviour and the environment. An integrative translational model, linking basic and experimental research with clinical research and population-based prospective-longitudinal studies is proposed for improving identification of critical core vulnerability and risk factors and core pathogenic mechanisms. The proposed framework is expected to allow a more stringent delineation of targeted preventive and therapeutic psychological interventions and an optimisation and better understanding of cognitive-behavioural therapies and other psychological interventions. Based on a European consultation process, a ‘Science of Behaviour Change' programme with the promise of improved diagnosis, treatment and prevention of both health-risk behaviour constellations and mental disorders is proposed.

Keywords:
Behaviour change, Psychology, Mental health, Psychotherapy, Health behaviour, Mental disorders
1.
American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, Text Revision (4th ed). Arlington, APA, 2000.
2.
American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders (5th ed). Arlington, APA, 2013.
3.
Andrews G, Charney DS, Sirovatka PJ, Regier DA: Stress-induced and fear circuitry disorders: refining the research agenda for DSM-V. Arlington, APA, 2009.
4.
Arch J, Craske M: First-line treatment: a critical appraisal of cognitive behavioral therapy developments and alternatives. Psychiatr Clin North Am 2009;32:525-547.
5.
Beesdo-Baum K, Knappe S: Developmental epidemiology of anxiety disorders. Child Adolesc Psychiatr Clin North Am 2012;21:457-478.
6.
Butler AC, Chapman JE, Forman EM, Beck AT: The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26:17-31.
7.
Cacioppo JT: Psychology is a hub science. Observer 2007;20:5,42.
8.
Craske M: Optimizing exposure therapy for anxiety disorders: an inhibitory learning and inhibitory regulation approach. Verhaltenstherapie 2015:25:♦♦-♦♦.
9.
Crawcour S, Leibing E, Ginzburg D, et al.: Transfer of manualized CBT for social phobia into clinical practice (SOPHO-PRAX): A study protocol for a cluster-randomized controlled trial. Trials 2012;13:70.
10.
David D, Montgomery GH: The scientific status of psychotherapies: a new evaluative framework for evidence-based psychosocial interventions. Clin Psychol Sci Pract 2011;18:89-99.
11.
Domschke K, Deckert J: Genetics of anxiety disorders - status quo and quo vadis. Curr Pharm Des 2012;18:5691-5698.
12.
Ehring T, Watkins ER: Repetitive negative thinking as a transdiagnostic process. Int J Cognit Psychother 2008;1:192-205.
13.
Emmelkamp PMG, David D, Beckers T, et al.: Advancing psychotherapy and evidence-based psychological interventions. Int J Methods Psychiatr Res 2014;23(suppl1):58-91.
14.
Etkin A, Wager TD: Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007;164:1476-1488.
15.
Fava GA, Tossani E, Bech P, et al.: Emerging clinical trends and perspectives of comorbid patterns of mental disorders. Int J Methods Psychiatr Res 2014;23(suppl1):92-101.
16.
Forand NR, De Rubeis RJ, Amsterdam JD: Combining medication and psychotherapy in the treatment of mental disorders; in Lambert MJ (ed): Bergin and Garfield's handbook of psychotherapy and behaviour change, ed 6. New York, John Wiley & Sons, 2013, pp 735-775.
17.
Fors EA, Bertheussen GF, Thune I, et al.: Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systemic review. Psychooncology 2011;20:909-918.
18.
Geller J, Dunn EC: Integrating motivational interviewing and cognitive behavioral therapy in the treatment of eating disorders: tailoring interventions to patient readiness for change. Cog Behav Pract 2011;18:5-15.
19.
Gloster AT, Wittchen H-U, Einsle F, et al.: Psychological treatment for panic disorder with agoraphobia: A randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011;79:406-420.
20.
Gloster AT, Sonntag R, Hoyer J, et al.: Treating treatment-resistant patients with panic disorder and agoraphobia using psychotherapy: a randomized controlled switching trial. Psychother Psychosom 2015;84:100-109.
21.
Goschke T: Dysfunctions of decision-making and cognitive control as transdiagnostic mechanisms of mental disorders: advances, gaps, and needs in current research. Int J Methods Psychiatr Res 2014;23(suppl1):41-57.
22.
Grilo CM, Crosby RD, Wilson GT, Masheb RM: 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol 2012;80:1108-1113.
23.
Gulliksson M, Burell G, Vessby B, et al.: Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention In Uppsala Primary Health Care Project (SUPRIM). Arch Intern Med 2011;171:134-140.
24.
Gustavsson A, Svensson M, Jacobi F, et al.: Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-779.
25.
Haber SN, Rauch SL: Neurocircuitry: a window into the networks underlying neuropsychiatric disease. Neuropsychopharmacology 2010;35: 1-3.
26.
Haro JM, Ayuso-Mateos JL, Bitter I, et al: ROAMER: A European Roadmap for Mental Health Research. Int J Methods Psychiatr Res 2014;23(suppl1):1-14.
27.
Haslam N, Lusher D: The structure of mental health research: networks of influence among psychiatry and clinical psychology journals. Psychol Med 2011;41:2661-2668.
28.
Hofmann SG, Smits JAJ: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69:621-632.
29.
Hofmann SG, Sawyer AT, Fang A, Asnaani A: Emotion dysregulation model of mood and anxiety disorders. Depress Anxiety 2012;29:409-416.
30.
Hutton P, Taylor PJ: Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analyses. Psychol Med 2013;22:1-20.
31.
Jones C, Hacker D, Cormac I, et al.: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 2012a;4:CD008712.
32.
Jones S, Mulligan LD, Law H, et al.: A randomized controlled trial of recovery focused CBT for individuals with early bipolar disorder. BMC Psychiatry 2012b;12:204.
33.
Kashikar-Zuck S, Sil S, Lynch-Jordan AM, et al.: Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia. J Pain 2012;14:492-501.
34.
Kessler RC, Berglund P, Demler O, et al.: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
35.
Kircher T, Arolt V, Jansen A, et al.: Effect of cognitive-behavioural therapy on neural correlates of fear conditioning in panic disorder. Biol Psychiatry 2012;73:93-101.
36.
Kirsch I: Changing Expectations. A Key to Effective Psychotherapy. Pacific, Brooks/Cole Publishing Co., 1990.
37.
Koob GF, Le Moal M: Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001;24:97-129.
38.
Kraemer HC: A mediator effect size in randomized clinical trials. Int J Methods Psychiatr Res 2014;23:401-410.
39.
Lueken U, Kruschwitz JD, Muehlhan M, et al.: How specific is specific phobia? Different neural response patterns in two subtypes of specific phobia. Neuroimage 2011;56:363-372.
40.
Merry SN, Stasiak K, Shepherd M, et al.: The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression: randomised controlled non-inferiority trial. BMJ 2012;344:e2598.
41.
Meyerbröker K, Morina N, Kerkhof GA, Emmelkamp PMG: Virtual reality exposure therapy does not provide any additional value in agoraphobic patients: a randomized controlled trial. Psychother Psychosom 2013;82:170-176.
42.
National Advisory Mental Health Council (NAMHC): Transformative neurodevelopmental research in mental illness. Washington, NIMH, 2008.
43.
Neshat-Doost HT, Dalgleish T, Yule W, et al.: Enhancing autobiographical memory specificity through cognitive training: an intervention for depression translated from basic science. Clin Psychol Sci 2013;1:84-92.
44.
Pellmar TC, Eisenberg L: Bridging Disciplines in the Brain, Behavioral, and Clinical Sciences. Washington DC, IOM/The National Academies Press, 2000.
45.
Raes F, Williams JMG, Hermans D: Reducing cognitive vulnerability to depression: a preliminary evaluation of MEmory Specificity Training (MEST) in inpatients with depressive complaints. J Behav Ther Exp Psychiatry 2009;40:24-38.
46.
ROAMER (A Roadmap for Mental Health Research in Europe). www.roamer-mh.org (accessed May 1, 2013).
47.
Robbins TW, Gillan CM, Smith DG, et al.: Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn Sci 2011;16:81-91.
48.
Roth AD, Fonagy P: What works for whom? A critical review of psychotherapy research. New York, Guilford, 1996.
49.
Sava F, Yates B, Lupu V, et al.: Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behaviour therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. J Clin Psychol 2009;65:36-52.
50.
Schoenmakers TM, de Bruin M, Lux IFM, et al.: Clinical effectiveness of attentional bias modification training in abstinent alcoholic patients. Drug Alcohol Depend 2010;109:30-36.
51.
Schumann G, Binder EB, Holte A, et al.: Stratiefied medicine for mental disorders. Eur Neuropsychopharmacol 2014;24:5-50.
52.
Siegle GJ, Thompson WK, Collier A, et al.: Towards clinically useful neuroimaging in depression treatment: Is subgenual cingulate activity robustly prognostic for depression outcome in cognitive therapy across studies, scanners, and patient characteristics? Arch Gen Psychiatry 2013;69:913-924.
53.
Shin LM, Liberzon I: The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010;35:169-191.
54.
Skuse DH: Endophenotypes and child psychiatry. Br J Psychiatry 2001;178:395-396.
55.
Teachman B: Mechanisms of change in CBT; in Emmelkamp PMG, Ehring T (eds): The Wiley Blackwell International Handbook of Anxiety Disorders, Vol. I. Oxford, Wiley-Blackwell, 2014.
56.
Van der Feltz-Cornelis CM, Adèr HJ: Randomization in psychiatric intervention research in the general practice setting. Int J Methods Psychiatr Res 2000;9:134-142.
57.
Van der Gaag M, Nieman DH, Rietdijk J, et al.: Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: A randomized controlled clinical trial. Schizophr Bull 2012;38:1180-1188.
58.
Van der Oord S, Ponsioen A, Geurts H, et al.: A pilot study of the efficacy of a computerized executive functioning remediation training with game elements for children with ADHD in an outpatient setting: outcome on parent and teacher-rated executive functioning and ADHD behavior. J Atten Disord 2014;18:699-712.
59.
Wampold BE: The great psychotherapy debate: Models, methods and findings. Mahwah, Erlbaum, 2001.
60.
Wang PS, Berglund PA, Olfson M, et al.: Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62:603-613.
61.
Williams JMG, Barnhofer T, Crane C, et al.: Autobiographical memory specificity and emotional disorder. Psychol Bull 2007;133:122-148.
62.
Wittchen H-U: Editorial. Int J Methods Psychiatr Res 2014;23(suppl1):v-vi.
63.
Wittchen H-U, Hoyer J: Was ist klinische Psychologie? Definitionen, Konzepte und Modelle; in dies (eds): Klinische Psychologie und Psychotherapie, ed 2. Berlin, Springer, 2011, pp 4-25.
64.
Wittchen H-U, Knappe S, Andersson G, et al.: The need for a behavioural science focus in research on mental health and mental disorders. Int J Methods Psychiatr Res 2014a;23(suppl1):28-40.
65.
Wittchen H-U, Knappe S, Schumann G: The psychological perspective on mental health and mental disorder research. Int J Methods Psychiatr Res 2014b;23(suppl1):15-27.
66.
Wittchen H-U, Jacobi F, Rehm J, et al.: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-679.
67.
World Health Organization (WHO): Tenth Revision of the International Classification of Diseases Chapter V (F): Mental and Behavioral Disorders (Including Disorders of Psychological Development). Clinical Descriptions and Diagnostic Guidelines. Geneva, WHO, 1991.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.